Short Interest Filing: What’s Next for Celsion Corporation (NASDAQ:CLSN) After Having More Shares Shorted?

November 29, 2016 - By Richard Conner   ·   0 Comments

Short Interest Filing: What's Next for Celsion Corporation (NASDAQ:CLSN) After Having More Shares Shorted?

The stock of Celsion Corporation (NASDAQ:CLSN) registered an increase of 7.83% in short interest. CLSN’s total short interest was 501,400 shares in November as published by FINRA. Its up 7.83% from 465,000 shares, reported previously. With 54,200 shares average volume, it will take short sellers 9 days to cover their CLSN’s short positions. The short interest to Celsion Corporation’s float is 2.34%. About 86,679 shares traded hands. Celsion Corporation (NASDAQ:CLSN) has declined 49.67% since April 26, 2016 and is downtrending. It has underperformed by 54.93% the S&P500.

Celsion Corporation is an oncology drug development company. The company has a market cap of $17.81 million. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). It currently has negative earnings. The Company’s pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

Insitutional Activity: The institutional sentiment decreased to 0.82 in Q2 2016. Its down 1.18, from 2 in 2016Q1. The ratio dived, as 2 funds sold all Celsion Corporation shares owned while 2 reduced positions. 3 funds bought stakes while 5 increased positions. They now own 3.89 million shares or 73.32% more from 2.25 million shares in 2016Q1.
Blackrock, a New York-based fund reported 2,305 shares. Seizert Prtn Ltd Com accumulated 0.01% or 120,022 shares. Geode Capital Mngmt Lc, a Massachusetts-based fund reported 81,576 shares. California Employees Retirement Sys has invested 0% of its portfolio in Celsion Corporation (NASDAQ:CLSN). Renaissance Techs Limited Liability Co, a New York-based fund reported 51,848 shares. Blackrock Fund Advisors holds 0% of its portfolio in Celsion Corporation (NASDAQ:CLSN) for 47,433 shares. Dimensional Fund Advsrs L P reported 20,420 shares or 0% of all its holdings. Moreover, Riggs Asset Managment Inc has 0% invested in Celsion Corporation (NASDAQ:CLSN) for 29 shares. Wells Fargo Mn last reported 1,500 shares in the company. Savings Bank Of America Corporation De reported 3,306 shares or 0% of all its holdings. Group One Trading L P last reported 0% of its portfolio in the stock. Focused Wealth Management accumulated 11 shares or 0% of the stock. Carroll Finance Inc has 0% invested in the company for 563 shares. Morgan Stanley has invested 0% of its portfolio in Celsion Corporation (NASDAQ:CLSN). Perritt Cap Mngmt has 0.07% invested in the company for 200,000 shares.

Insider Transactions: Since June 16, 2016, the stock had 5 insider purchases, and 0 insider sales for $40,770 net activity. $6,250 worth of shares were bought by Martinez Alberto R Jr on Tuesday, August 16. Tardugno Michael H had bought 7,500 shares worth $10,125 on Thursday, June 16.

CLSN Company Profile

Celsion Corporation (Celsion), incorporated on May 17, 2000, is an oncology drug development company. The Firm is focused on developing a portfolio of cancer treatments, including directed chemotherapies, deoxyribonucleic acid (DNA)-mediated immunotherapy and ribonucleic acid (RNA) therapies. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company’s pipeline also includes GEN-1, a DNA mediated immunotherapy for the localized treatment of ovarian and brain cancers. The Firm has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer RNA.

More important recent Celsion Corporation (NASDAQ:CLSN) news were published by: Marketwatch.com which released: “Celsion Corp.” on October 10, 2010, also Globenewswire.com published article titled: “Celsion Corporation Reports Third Quarter 2016 Financial Results and Provides …”, Prnewswire.com published: “Celsion Corporation Announces Appointment of Harriet Shelare to Director …” on April 27, 2015. More interesting news about Celsion Corporation (NASDAQ:CLSN) was released by: Globenewswire.com and their article: “Celsion Corporation Announces $6 Million Registered Direct Offering” with publication date: June 13, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>